Overview

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Status:
Completed
Trial end date:
2021-07-06
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Emalex Biosciences Inc.
Collaborators:
Nuventra
Syneos Health
Treatments:
Ecopipam
Mefenamic Acid
Valproic Acid